We were delighted to welcome Jason Ehrlich, Co-Founder and CEO of Ollin Biosciences onto the BioHub. Ollin are a clinical-stage biotechnology company focused on advancing next-generation therapies form serious eye diseases, including wet age-related macular degeneration anddiabetic macular edema.
Before launching Ollin, Jason served as Chief MedicalOfficer and Chief Development Officer at Kodiak Sciences, where he led clinical development in retinal disease. Earlier in his career, he held senior leadership roles at Genentech, one of the pioneers in biologic medicines, helping advance therapies that have transformed care for patients with vision-threatening conditions.
Trained as both a physician and a scientist, Jason brings arare blend of clinical insight, translational research expertise, and strategic leadership. His career sits at the intersection of medicine, innovation, and company building — with a clear focus: delivering meaningful, durable therapies to patients who risk losing their sight.
